BLOCKING Act Would Delay Patient Access to Cheaper Prescription Drugs

The Following is a statement from Krisztina Pusok, Director of Policy and Research at ACI: “ACI strongly supports Congressional efforts seeking to lower prescription drug prices for patients, consumers, and taxpayers. Unfortunately, the “Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act,” would achieve the exact opposite of what it is […]

Taxpayer and Consumer Coalition Objects to Impeding Generic Drug Competition

A coalition taxpayer and consumer groups sent a letter to Illinois House members explaining that H.B. 4900 — the Illinois Generic Drug Pricing Fairness Act — would seek to target generic drug pricing and impede generic competition, while leaving more expensive name brand drugs unaffected.  While working families, small businesses, seniors, and especially society’s most […]

Organizations Call On Congress to Encourage Prescription Competition

A large group of organizations are calling on Congress to remove regulatory barriers in order to allow generic drug makers to have access to brand name drugs for FDA testing and approval.  The bill would encourage competitive entry once brand name drug patents have expired, permitting new rivals to provide lower cost drugs to doctors […]

Coalition Sends a Letter to Congress in Support of the CREATES Act

The CREATES Act, if enacted, would remove industry entry barriers, encourage market competition, bring lower cost drugs to market, and benefit patients.  The following is the coalition letter send to the Senate Judiciary Committee (click here for a printable version): ————– July 12, 2016   The Honorable Chuck Grassley The Honorable Patrick J. Leahy Committee on the Judiciary United States Senate 224 […]